Prediction of Intestinal Drug Absorption Properties by Three-Dimensional Solubility Parameters
- 482 Downloads
Purpose. The purpose of this study was to investigate the use of solubility parameters for the prediction of gastrointestinal absorption sites and absorption durations of drugs.
Methods. Three-dimensional solubility parameters of drug substances were calculated using an advanced parameter set based on the group contribution methods of Fedors and Van Krevelen/Hoftyzer. The results of the calculations were illustrated via Bagley diagram and related to absorption data reported in the literature.
Results. Solubility parameters of drugs which are known to be absorbed over a long period in human's digestive tract were found in a limited area within the Bagley diagram. From the three-dimensional solubility parameters of these substances, a region for optimal absorption with the centre coordinates δv = 20.3 (J ⋅ cm−3)0.5 and δh = 11.3 (J ⋅ cm−3)0.5 could be derived. Drugs with absorption sites along the whole gastrointestinal tract were found in this area. Drugs which are preferably absorbed from upper parts of the intestine are located in another typical region with partial solubility parameters δh of more than 17 (J ⋅ cm−3)0.5.
Conclusions. The method which is presented in this paper appears as a simple but effective method to estimate the absorption behaviour of new substances in drug research and development.
Unable to display preview. Download preview PDF.
- 1.W. I. Higuchi, N. F. H. Ho, J. Y. Park, and I. Komiya. Rate-limiting steps and factors in drug absorption. In L. F. Prescott, W. S. Nimmo. Drug absorption, MTP Press Limited, Lancaster UK, 1981, pp. 35–60.Google Scholar
- 2.N. Rouge, P. Buri, and E. Doelker. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int. J. Pharm. 136:117–139 (1996).Google Scholar
- 5.L. X. Yu, E. Lipka, J. R. Crison, and G. L. Amidon. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv. Drug Deliver. Rev. 19:359–376 (1996).Google Scholar
- 6.G. M. Grass. Simulation models to predict oral drug absorption from in vitro data. Adv. Drug Deliver. Rev. 23:199–219 (1997).Google Scholar
- 7.C. Hansch and J. M. Clayton. Lipophilic character and biological activity of drugs II: The parabolic case. J. Pharm. Sci. 62:1–21 (1973).Google Scholar
- 9.C. M. Hansen. The universality of the solubility parameter. Ind. Eng. Chem. Res. Devel. 8:2–11 (1969).Google Scholar
- 12.J. L. Mokrosz, B. Duszynska, and L. Strekowski. Topological inidices in correlation analysis. Part 3: The modelling of hydrophobic properties using molecular connectivity and shape indices. Pharmazie 47:538–541 (1992).Google Scholar
- 15.R. Gröning, W. Sakran, F.-J. Braun, M. S. Adel, A: Abd El-Bary, and M. F. El-Miligi. Rectal absorption of drugs—indirect characterisation of the rectal membrane using the Bagley diagram and in vivo drug absorption data. Eur. J. Pharm. Biopharm. 42(Suppl.):55 S (1996).Google Scholar
- 16.R. F. Fedors. A method for estimating both the solubility parameters and molar volumes of liquids. Polymer Engin. Sci. 14:147–154 (1974).Google Scholar
- 17.D. W. Van Krevelen and P. J. Hoftyzer. Properties of polymers. Their estimation and correlation with chemical structures. Elsevier, Amsterdam, 1976.Google Scholar
- 18.J. Breitkreutz, J. Bolten, and R. Gröning. Publication in progress. The computer program SPWin 2.1 requires Microsoft Windows™ 3.1 or higher. It is available by correspondance to the author.Google Scholar
- 19.A. F. M. Barton. Solubility parameters. Chem. Rev. 75:731–753 (1975).Google Scholar
- 20.E. B. Bagley, T. P. Nelson, and J. M. Scigliano. Three-dimensional solubility parameters and their relationship to internal pressure measurements in polar and hydrogen bonding solvents. J. Paint Technol. 43:35–42 (1971).Google Scholar
- 22.A. H. Staib. Methods used to investigate drug absorption in the colon: A review. Workshop “Colon-Resorption und Colon-Targeting”. Düsseldorf, 1996.Google Scholar
- 24.J. M. Cedarbaum. Clinical Pharmacokinetics of Anti-Parkinsonian Drugs. Clin. Pharmacokin. 13:141–178 (1987).Google Scholar
- 25.W. H. Barr, E. M. Zola, E. L. Candler, S. M. Hwang, A. V. Tendolkar, R. Shamburek, B. Parker, M. D. Hilty. Differential absorption of amoxicillin from the human small and large intestine. Clin. Pharmacol. Therap. 56:279–285 (1994).Google Scholar
- 26.J. Drewe, C. Beglinger, and T. Kissel. The absorption site of cyclosporin in the human gastrointestinal tract. Br. J. Clin. Pharmac. 30:35–39 (1992).Google Scholar
- 28.S. S. Davis, N. Washington, A. H. Short, V. A. John, P. Lloyd, S. M. Walker. Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy Br. J. Clin. Pharmac. 26:435–443 (1988).Google Scholar
- 30.R. A. Conradi, P. S. Burton, and R. T. Borchardt. Physicochemical and biological factors that influence a drug's cellular permeability by passive diffusion. In V. Pliska, B. Testa, H. van de Waterbeemd, Lipophilicity in drug action and toxicology, VCH Verlagsgesellschaft, Weinheim, Germany, 1996, pp. 233–252.Google Scholar